Vanda Pharmaceuticals Inc. announced that NEREUS (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in adults, marking the first new prescription medicine approved for this condition in more than 40 years. An innovative direct-to-consumer order platform is now available through nereus.us. Motion sickness affects an estimated 65 to 78 million Americans?roughly 25 to 30% of adults?during everyday travel by car, plane, or boat.
For decades, patients have had no meaningful new treatment options. NEREUS is available now by prescription directly through nereus.us and retail pharmacies nationwide. Through the dedicated direct-to-consumer portal at nereus.us, patients with a valid prescription can access NEREUS at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose.
Throughout history, motion sickness has repeatedly undermined military effectiveness and human exploration. During Napoleon's 1798 Egyptian campaign, soldiers in his newly formed camel corps?known as the "ships of the desert"?suffered debilitating nausea and vomiting from the animals' swaying gait, rendering many unfit for battle and even affecting Napoleon himself. On D-Day in 1944, thousands of Allied paratroopers endured violent air sickness during turbulent flights over the English Channel before they even reached Normandy.
In the space age, nearly 70% of astronauts have faced space adaptation syndrome, a form of motion sickness that has challenged every major space program since the 1960s. For more than four decades, no new pharmacologic treatment emerged to address this ancient affliction?until today. Motion sickness may occur when the brain receives conflicting signals from the eyes, inner ear, and body while on motion.
This sensory mismatch is believed to trigger the release of substance P, which activates NK-1 receptors in the central nervous system and ultimately leads to nausea and vomiting. NEREUS works by blocking these receptors, interrupting the vomiting pathway. The U.S. Food and Drug Administration approved NEREUS on December 30, 2025, following two pivotal Phase 3 clinical trials?Motion Syros and Motion Serifos?conducted under real-world conditions on the open sea.
Both studies demonstrated that NEREUS significantly prevented vomiting compared to placebo, confirming the drug's effectiveness in actual sea travel conditions. It is the first new prescription option for people with history of motion sickness in over 40 years. It employs a novel mechanism as a selective, high-affinity antagonist of human substance P/NK-1 receptors.
It offers simple dosing with just one or two capsules a day taken approximately an hour before travel. The commercial availability of NEREUS marks a historic milestone in addressing this highly prevalent physiological reaction to motion that has plagued humans for millennia.
